CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment

MT Newswires Live2025-02-27

CARsgen Therapeutics' (HKG:2171) equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.

The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.

Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.

UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2514987977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 18:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514987977","market":"hk","top_or_hot":-1,"title":"CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment","media":"MT Newswires Live","content":"<html><body><p> CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (HKG:2171) equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.</p><p>The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.</p><p>Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&amp;D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.</p><p>UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-27 18:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (HKG:2171) equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.</p><p>The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.</p><p>Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&amp;D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.</p><p>UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BMPRXQ63.HKD","symbol_name":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514987977","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514987977","pubTimestamp":1740651198,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CARsgen Therapeutics'  equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC","02171":"科济药业-B","BK4543":"AI","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4609":"英伟达持仓股","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LENZ":"Therapeutics","BK1161":"生物科技","BK1587":"次新股","BK4141":"半导体产品","BK1574":"生物医药B类股","BK4139":"生物科技","BK1585":"昨日强势股","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC"},"translate_title":"第三方投资后，CARsgen Therapeutics将削减生物技术部门的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"02171":0.9},"content_text":"CARsgen Therapeutics' (HKG:2171) equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514987977","isCrawlerRequest":true}